BRAF inhibitors have been largely ineffective in BRAF-mutant colorectal cancer, MEK inhibitors have had little impact in a variety of RAS-mutated tumors, and PI3K inhibitors have yielded disappointing results in tumors harboring alterations in PTEN and PI3Kα [39, 40]. This evidence concerns the gene BRAF and colorectal cancer.